The Match-R PDX project


XenTech launches a new line of PDX models of acquired resistance to last generation targeted therapies


Development of 75 PDX models from patients with acquired resistance to latest targeted drugs

A preclinical platform to identify resistance mechanisms and develop new therapeutic strategies


Background: Patients whose tumor harbor specific driver molecular alterations benefit from targeted therapies. These molecules have a good efficacy profile but patients’ responses are generally short-lived due to the emergence of adaptive/secondary resistance. Disposing of clinically relevant models to identify the resistance mechanisms at play and perform preclinical POC studies is critical to develop new therapeutic strategies translating into increased patient survival.



The MATCH-R precision medicine trial led by Gustave Roussy (NCT02517892) will enroll 600 patients treated with targeted therapies in phase I/II studies between 2014 and 2020. Its main goal is to study the molecular evolution of tumors subjected to targeted therapies and developing acquired resistance.

Biopsies from progressing tumor lesions will be performed in 300 patients having developed resistance following initial response and used to generate PDX models that will be expanded under therapy to confirm their resistance status and molecularly characterized by WES and RNAseq.


Click images below for

Already available Models                                                                                                                                       Models in Development for 2018